Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CEO Sells $1,034,339.98 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 34,501 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $29.98, for a total transaction of $1,034,339.98. Following the transaction, the chief executive officer owned 23,337 shares in the company, valued at $699,643.26. This represents a 59.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Maze Therapeutics Price Performance

MAZE stock opened at $31.26 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 17.88 and a quick ratio of 17.88. The company’s 50-day moving average is $26.02 and its 200-day moving average is $35.64. The stock has a market capitalization of $1.73 billion, a PE ratio of -12.36 and a beta of 2.14. Maze Therapeutics, Inc. has a 1 year low of $10.98 and a 1 year high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last issued its earnings results on Tuesday, May 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million during the quarter. Equities research analysts expect that Maze Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Institutional Trading of Maze Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Seven Fleet Capital Management LP bought a new position in shares of Maze Therapeutics in the first quarter valued at approximately $917,000. Bank of America Corp DE raised its position in Maze Therapeutics by 961.3% in the 1st quarter. Bank of America Corp DE now owns 195,084 shares of the company’s stock valued at $5,823,000 after buying an additional 176,703 shares during the last quarter. Royal Bank of Canada raised its position in Maze Therapeutics by 214.1% in the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock valued at $61,000 after buying an additional 1,383 shares during the last quarter. Exome Asset Management LLC purchased a new position in Maze Therapeutics during the 1st quarter worth $2,642,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in Maze Therapeutics by 111.3% during the 1st quarter. The Manufacturers Life Insurance Company now owns 14,570 shares of the company’s stock worth $435,000 after acquiring an additional 7,673 shares during the last quarter.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Truist Financial lowered their target price on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, April 14th. JPMorgan Chase & Co. lifted their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the company an “overweight” rating in a research report on Tuesday, March 31st. BTIG Research restated a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, March 25th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Two analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Maze Therapeutics presently has an average rating of “Buy” and a consensus price target of $66.00.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.